Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment

NCT01424436 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01424436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01424436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
May 19, 2010
Completion date
December 8, 2011
Enrollment
19 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease